Table 3 Characteristics of patients with regard to T790M mutation status at disease progression (N = 75)
Characteristics | T790M(-) (N = 33) | T790M(+) (N = 42) | P values |
|---|---|---|---|
Age, y | 65.0 (58.5–73.5) | 63.5 (56.0–68.3) | 0.313 |
Male sex | 14 (42) | 17 (41) | 0.865 |
ECOG | Â | Â | Â |
   0–1 | 30 (91) | 39 (93) | 0.999 |
   ≥2 | 3 (9) | 3 (7) |  |
Smoking status | Â | Â | Â |
   Current or former smoker | 7 (21) | 14 (33) | 0.246 |
   Never-smoker | 26 (79) | 28 (67) |  |
Stage | Â | Â | Â |
   IIIB/IV | 30 (91) | 38 (91) | 0.999 |
   Post-operative recurrence | 3 (9) | 4 (10) |  |
EGFR mutation | Â | Â | Â |
   L858R | 15 (46) | 18 (43) | 0.672 |
   Exon 19 deletion | 16 (49) | 23 (55) |  |
   Others†| 2 (6) | 1 (2) |  |
First-line EGFR TKI | Â | Â | Â |
   Gefitinib | 7 (21) | 8 (19) | 0.472 |
   Erlotinib | 12 (36) | 21 (50) |  |
   Afatinib | 14 (42) | 13 (31) |  |
Initial presentation | Â | Â | Â |
   Malignant pleural effusion | 11 (33) | 14 (33) | 0.999 |
   Malignant pericardial effusion | 0 (0) | 3 (7) | 0.251 |
   Brain metastasis | 11 (33) | 16 (38) | 0.670 |
   Liver metastasis | 1 (3) | 6 (14) | 0.126 |
   Bone metastasis | 18 (55) | 21 (50) | 0.696 |
Best response to EGFR TKI | Â | Â | Â |
   Partial response | 21 (64) | 30 (71) | 0.420 |
   Stable disease | 9 (27) | 11 (26) |  |
   Progressive disease | 3 (9) | 1 (2) |  |
Time to progression, mo | 12.4 (7.1–19.9) | 13.7 (7.9–20.0) | 0.898 |
Duration of first-line TKI, mo | 17.3 (10.1–25.4) | 17.0 (10.7–24.5) | 0.709 |
Overall survival, mo‡ | 35.5 (23.8–56.0) | 36.2 (22.0–52.0) | 0.572 |